Myosteatosis differed in the reference group in all qualities except for

An added Cox regression analysis which includes only sufferers without intravenous contrast CT yielded equivalent final results, with only age 86 year.Myosteatosis differed from the reference group in all characteristics except for remedy technique and complication prices (Table 1).J. Clin. Med. 2021, ten,6 ofTable 1. Baseline characteristics of individuals having a pelvic ring injury. All Patients (N = 199) Gender Male Female Age at injury (imply ?SD) BMI (kg/m2 ) (imply ?SD) BMI 25 BMI 30 SMI (cm2 /m2 ) (mean ?SD) Male Female Mean muscle HU (mean ?SD) Sarcopenia Myosteatosis CCI (mean ?SD) Injury mechanism Low-energy trauma High-energy trauma ISS (imply ?SD) Injury classification Form A Type B Variety C Treatment Non-operative Operative Complications 30 days 70 (35) 129 (65) 78 ?eight 25 ?5 22 (11) 177 (89) 41.6 ?9.three 49.9 ?7.2 37.2 ?7.0 31.1 ?10.three 76 (38) six? 122 (61) 77 (39) 14 ?11 68 (34) 113 (57) 18 (9) 165 (83) 34 (17) 58 (30) Reference Group (N = 98) 39 (40) 59 (60) 75 ?7 25 ?four 50 (51) 48 (49) 46.1 ?eight.five 53.eight ?four.7 41.0 ?6.3 37.3 ?7.five five? 48 (49) 50 (51) 15 ?12 25 (26) 61 (62) 12 (12) 79 (81) 19 (19) 28 (29)Sarcopenia (N = 36) 17 (47) 19 (53) 79 ?8 24 ?four 21 (59) 15 (42) 36.7 ?6.9 43.two ?2.9 30.eight ?two.7 34.7 ?6.7 36 (100) 5? 25 (69) 11 (31) 11 ?9 13 (36) 20 (56) three (eight)p-Value 0.Myosteatosis (N = 35) eight (23) 27 (77) 79 ?eight 27 ?six 13 (37) 22 (63) 42.5 ?8.2 53.3 ?six.4 39.three ?five.four 21.two ?3.7 35 (one hundred) 5? 22 (63) 13 (37) 16 ?12 14 (40) 20 (57) 1 (three)p-Value 0.Sarcopenia + Myosteatosis (N = 30) six (20) 24 (80) 83 ?7 24 ?four 22 (73) eight (27) 32.0 ?four.9 38.five ?five.6 30.five ?three.2 18.2 ?five.3 30 (100) 30 (one hundred) 6? 27 (90) three (10) 10 ?9 16 (53) 12 (40) two (7)p-Value 0.0.03 0.0.05 0.0.001 0.0.0.0.0.06 0.41 0.0.001 0.13 0.0.0.001 0.0.06 0.0.65 0.0.03 0.0.46 31 (86) five (14) 9 (25) 28 (80) 7 (20) 13 (37)0.77 27 (90) three (ten) eight (27)0.0.0.0. Numbers are expressed as N ( ) unless otherwise specified. Reference group: all sufferers with out sarcopenia and/or myosteatosis. Sufferers with or with out sarcopenia and/or myosteatosis were compared with the reference group. Statistically substantial final results are presented in bold. BMI: physique mass index, SMI: skeletal muscle index, HU: Hounsfield units, CCI: Charlson Comorbidity Index, ISS: injury severity score.J. Clin. Med. 2021, 10,7 ofFigure 4. Venn diagram showing individuals with sarcopenia, myosteatosis, each or neither.3.2. Mortality and Survival Evaluation of mortality rates at distinct timepoints revealed that individuals with sarcopenia had an increased mortality threat 3 years just after the injury (Table two). Patients with sarcopenia and myosteatosis had an enhanced mortality danger all round.